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Novel EGFR-TK Inhibitor EKB-569 Inhibits Hepatocellular 
Carcinoma Cell Proliferation by AKT and MAPK Pathways
Epidermal growth factor receptor (EGFR)–targeted therapies have been effective in some 
cancers, but not in hepatocellular carcinoma (HCC). The aim of this study was to 
investigate the drug potential to overcome multi-drug resistance in HCC cells. Thirteen 
drug-sensitive HCC cells were assessed using the CCK-8 assay. G0-G1 arrest was measured 
by FACS. Western blot analysis was used to detect the key enzymes in both the Ras/Raf 
and PI3K pathways. When establishing the IC50 of HCC to several drugs, including EKB-
569, sorafenib, erlotinib, gefitinib, pazopanib, and brivanib, SK-Hep1 cells treated with 
EKB-569 have shown the highest (72.8%-86.4%) G0-G1 arrest and decreased the 
phosphorylation of AKT and ERK at the protein level. We found that EKB-569 had higher 
efficacy in HCC, compared to first generation, reversible EGFR-TK inhibitors. Furthermore, 
the combination of sorafenib and EKB-569 showed a synergistic effect to inhibit 
proliferation of SNU-475, previously the most resistant cell to EGFR-TKIs. Therefore, novel 
EKB-569 in combination with sorafenib may be able to overcome HCC resistance to EGFR-
TK inhibitors.
Key Words: Epidermal Growth Factor Receptor (EGFR)-Tyrosine Kinase Inhibitors (TKIs); 
EKB-569; Multi-drug Resistance; Hepatocellular Carcinoma (HCC) Cells
Heesue Kim
1 and Ho Yeong Lim
2 
1Department of Clinical Research, Samsung 
Biomedical Research Institute; 
2Division of 
Hematology-Oncology, Department of Medicine, 
Samsung Medical Center, Sungkyunkwan University 
School of Medicine, Seoul, Korea
Received: 29 June 2011
Accepted: 5 October 2011
Address for Correspondence:
Ho Yeong Lim, MD
Division of Hematology-Oncology, Department of Medicine, 
Samsung Medical Center, 81 Irwon-ro, Gangnam-gu, Seoul 
135-710, Korea 
Tel: +82.2-3410-0914, Fax: +82.2-3410-1754
E-mail: hoylim@skku.edu
This study was supported by a Samsung Biomedical Research 
Institute grant (#SBRI C-A9-236).
http://dx.doi.org/10.3346/jkms.2011.26.12.1563  •  J Korean Med Sci 2011; 26: 1563-1568
ORIGINAL ARTICLE
Oncology & Hematology
INTRODUCTION
With an annual incidence of over 560,000 deaths, hepatocellular 
carcinoma (HCC) is the sixth most common malignancy and 
the third leading cause of cancer-related mortality worldwide 
(1). Liver cancer accounts for 4% of all cancers and more than 
70% of all liver cancers occur in Asia, with high incidence of liv-
er cancer in the East Asian countries, including Korea, China, 
and Japan (2). Recent research has demonstrated that Ras/Raf/
MAPK and PI3K/AKT/mTOR pathways appear to modulate 
important signaling sequences in the development and pro-
gression of HCC. The Ras/Raf/MAPK pathway is activated in 
the majority of advanced HCCs, as a result of increased signal-
ing induced from upstream growth factors, such as epidermal 
growth factor (EGF), hepatocyte growth factor (HGF), or insu-
lin-like growth factor (IGF), and also because of inactivation of 
tumor suppressor genes, including PTEN (3, 4). The PI3K/AKT/
mTOR signaling pathway plays a pivotal role in HCC and was 
found activated in 30%-50% of HCC cases (5). The etiology of 
HCC tumorigenesis and recurrence is currently poorly under-
stood, and there is urgent need to find effective targets to treat 
HCC and to prevent tumor recurrence.
  Sorafenib is a multi-targeted tyrosine kinase inhibitor acting 
on vascular endothelial growth factor receptor (VEGFR), plate-
let-derived growth factor receptor (PDGFR), raf, c-kit, and flt-3, 
and has been shown to inhibit HCC-induced proliferation and 
angiogenesis. Recent clinical trials for sorafenib treatment of 
advanced HCC demonstrated promising results (6-8). Various 
other novel drugs are currently under study to enhance efficacy 
and reduce toxicity in the treatment of advanced HCC. Brivanib 
has been shown to demonstrate potent and selective inhibition 
of both VEGFR and FGFR-1 tyrosine kinases (9) and inhibited 
the growth of HCC xenografts in vivo (10). Multicenter phase III 
studies involving brivanib in patients with advanced HCC are 
ongoing. Pazopanib is another potent, multi-target receptor ty-
rosine kinase inhibitor of VEGFR-1, -2, and -3, PDGFR-α and -β, 
and c-kit, and has demonstrated in vivo anti-tumor effect in HCC 
xenografts (11).
  The epidermal growth factor receptor (EGFR) signaling path-
way is an important mediator of cancer cell oncogenesis, prolif-
eration, maintenance, and survival. For this reason, it has long 
been an attractive candidate as anticancer drug target (12). Both 
gefitinib and erlotinib, the first-generation EGFR tyrosine kinase 
inhibitors (TKIs), have single-agent activity against various can-
cer cells, including advanced non-small cell lung cancer (NSCLC); 
thus, erlotinib improved survival when given as salvage treat-
ment after chemotherapy in NSCLC (13, 14), but showed only a 
minor effect in HCC (15, 16). The second generation of EGFR Kim H, et al.  •  EKB-569 Inhibits SK-Hep1 Cell Proliferation 
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TKIs, including EKB-569, is now emerging from the developmen-
tal pipeline and is being introduced into clinical trials. In addi-
tion to blocking EGFR signaling, these novel EGFR TKIs target 
additional members of the ErbB family, such as HER-2 or other 
downstream or parallel pathways, including the VEGFR path-
way. EKB-569 is a potent, low molecular weight, selective and 
second-generation irreversibly binding inhibitor of EGFR-TK 
activity (17).
  The purpose of this in vitro study was to investigate the effects 
of the second-generation compound (EKB-569) in HCC. EKB-
569 was evaluated for its potential as part of a chemosensitizing 
combination treatment with sorafenib, in tailored therapies for 
resistant tumors. 
MATERIALS AND METHODS
Cell culture 
Four human hepatoma cell lines (Hep3B, Huh-7, SK-Hep1, and 
HepG2) were cultured in DMEM medium (Life Technologies, 
Grand Island, NY, USA). Similarly, SNU-354, SNU-368, SNU-398, 
SNU-423, SNU-449, SNU-475, SNU-739, SNU-886, and SNU-878 
cells were cultured in RPMI-1640 medium, supplemented with 
10% fetal bovine serum (FBS) and antibiotics (Life Technologies). 
The cultured cells were incubated in 5% CO2 at 37°C.
Chemicals and antibodies 
Sorafenib, erlotinib, gefitinib, pazopanib, and brivanib were ob-
tained from LC Laboratories (Woburn, MA, USA). EKB-569 was 
obtained from Wyeth (Pfizer Inc., NY, NY, USA). Primary anti-
bodies against either total or phosphorylated (p) AKT (Ser473), 
ERK1/2 (Thr 202/204), STAT3, and EGFR (Cell Signaling Tech-
nology, Danvers, MA, USA), cyclinD1, p27, and Rb (BD biosci-
ences, San Diego, CA, USA), β-actin (Sigma-Aldrich, St. Louis, 
MO, USA), CDK4, P21, phospho-Rb, anti-rabbit IgG horserad-
ish peroxidase, and mouse IgG were obtained from Santa Cruz 
Biotechnology, Inc. (Santa Cruz, CA, USA). Phosphatase inhibi-
tor cocktail (Sigma-Aldrich, St. Louis, MO, USA), cell counting 
kit-8 (CCK-8; Dojindo Molecular Technologies Inc., Kumamoto, 
Japan), and Restore-Stripping Buffer for Western blot were ob-
tained from Pierce (Rockford, IL, USA).
Drug treatment and cell viability
Thirteen exponentially growing HCC cell lines were trypsinized 
and plated at 4-5 × 10
3 cells/mL in 96-well culture plates. After 
24 hr incubation, cells were treated for 72 hr with serial three-fold 
dilutions of 10 μM for each drug. Each experiment was repeat-
ed at least three times. Cell viability was measured by the CCK-
8 assay. The optical density (OD) was measured using a spec-
trophotometer (Molecular Devices Co., Sunnyvale, CA, USA). 
Graph and fold was calculated with PRISM Software (GraphPad 
Software, CA, USA).
Cell cycle analysis by flow cytometry
Approximately 2 × 10
6 cells were trypsinized, washed twice with 
PBS, and fixed in 70% ice-cold ethanol for 1 hr. The samples were 
then concentrated by removing the ethanol and exposed to 100 
μg/mL RNase A (8 μL; Sigma-Aldrich) for 30 min, at 37°C. Cel-
lular DNA was stained with propidium iodide. Cell cycle distri-
butions were determined using flow cytometry (BD FACS Cali-
ber; Biosciences, San Jose, CA, USA).
Western blot analysis
Protein extraction was done by protein extraction solution (iN-
tRON Biotechnology, Seongnam, Korea) with a protease inhibi-
tor cocktail (Sigma-Aldrich) and protein quantification was per-
formed by a BCA Protein Assay kit (Pierce). Equal amounts of 
protein (50 μg) were electrophoresed on NuPAGE 4%-12% Bis-
Tris Gels (Invitrogen, Carlsbad, CA, USA), and transferred to 
Immobilon-P membrane (Millipore, Billerica, MA, USA). The 
membranes were then blocked with 5% non-fat milk and probed 
with the primary antibody (1:1,000) in 1 × TBS with Tween-20 
buffer (BIOSESANG Inc., Seongnam, Korea). Then, the blots 
were visualized under enhanced chemiluminescence (Amer-
sham, Buckinghamshire, UK), according to the manufacturer’s 
instructions.
RESULTS
Response of human hepatoma cell lines to EGFR inhibitor 
and sorafenib
To explore the potential anti-cancer agent on HCC, we examined 
Table 1. IC50 of HCC cell lines to several drugs
Drugs Hep3B HepG2 SK-HEP-1 Huh-7 SNU-354 SNU-368 SNU-398 SNU-423 SNU-449 SNU-475 SNU-739 SNU-886 SNU-878
Gefitnib  > > > > 2.2 > > > > > > 9.8 >  
Erlotinib > > > > > > > > > > > > >
EKB-569 2.3 > 2.3 1.9 > > * 2.1 > > > > 7.3
Sorafenib 8 5.1 5.8 4.2 9.1 8.8 * 9.4 9.1 > > 8.8 8.1
Pazopanib > > > > > > > > > > > > >
Brivanib > > > 8.6 > > > > > > > > >
Effect of sorafenib and EGFR-targeted therapies on the growth of human hepatoma cell lines. Thirteen hepatoma cell lines were treated with sorafenib, VGFR, and EGFR-target-
ed therapies for 24 hr at concentrations ranging between 3.3 nM and 10 µM. Cellular viability was assessed by the CCK-8 assay. IC50 value was calculated using PRISM Soft-
ware. In general, values over 10 µM showed significant change, indicated by “ > ”; asteriks (*) indicates data not shown.  Kim H, et al.  •  EKB-569 Inhibits SK-Hep1 Cell Proliferation 
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the effects of multi-targeted tyrosine kinase inhibitors, and first 
and second-generation EGFR-targeted agents on the growth of 
human hepatoma cell lines (Table 1). Each test was performed 
with drug concentration at a serial 3-fold dilution (10 μM to 3.3 
nM) and similar results were obtained from three independent 
experiments. Although we could not find a drug most effective 
in all 13 cell lines (Table 1), the IC50 values of the cell lines treat-
ed with the irreversible ErbB inhibitor (EKB-569) were lower 
than those of cells treated with gefitinb, erlotinib, brivanib, and 
pazopanib, except for sorafenib, which seemed the most effec-
tive of the drugs. In addition, Hep3B, HepG2, SK-Hep1, Huh-7, 
SNU-423, SNU-739 and SNU-878 cells treated with EKB-569 
showed better results even than sorafenib treatment. All drugs 
showed IC50 values > 10 μM in SNU-398, SNU-475 and SNU-
739. In the SNU-398 cell line in particular, the IC50 values of both 
sorafenib and EKB-569 were less than 5 μM in replicate indepen-
dent experiments (data not shown). However, subsequent sub-
culture altered the response to the drugs. Therefore additional 
experiments were not performed, and EKB-569 and sorafenib 
were indicated as asteriks in Table 1. SNU-739 cells treated with 
IGF-1R inhibitor and other second generation EGFR-TKIs (data 
not shown) showed IC50 < 10 μM. SK-Hp1, Huh-7, SNU-447 and 
SNU-739 cells treated with brivanib and SNU-449 and SNU-886 
cells treated with EKB-569 showed values close to IC50 of 10 μM. 
However, in cell viability experiments with drugs (including un-
published data), the results obtained for SNU-475 cells could 
not be reproduced in all 13 HCC cell lines. Therefore, for further 
study of EKB-569 mechanism, we chose the cell line SK-Hep1 
which was sensitive to EKB-569, and the cell line SNU-475, which 
showed the greatest resistance to the drug. 
Increase of G0-G1 arrest by EKB-569 
To examine how EKB-569 inhibits cell proliferation, we analyzed 
G0-G1 arrest by flow cytometry, after SK-Hep1 and SNU-475 cells 
were treated with EKB-569 for 24 hr. In SK-Hep1 cells, G0-G1 arrest 
was increased with approximately 13.6% (from 72.8% to 86.4%) 
with 1 μM EKB-569. However, in SNU-475 cells, G0-G1 arrest only 
increased 5.4% (from 75.8% to 81.2%) even with 5 μM EKB-569 
(Fig. 1). 
EKB-569 decreased the phosphorylation of AKT and ERK 
at the protein level
SK-Hep1 and SNU-475 cells were treated with the indicated con-
centrations of EKB-569 for 24 hr (Fig. 2). In SK-Hep1 cells, after 
treatment with EKB-569, we found down-regulation of phos-
phorylated ERK and AKT and up-regulation of p21 in a dose-
dependent manner; however, there were no significant differ-
ences in the protein levels of cell cycle-related protein, CDK4, 
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Fig. 1. Detection of EKB-569-induced G0-G1 arrest by FACS analysis. SK-Hep1 cells were treated with the indicated concentrations of EKB-569 for 24 hr. EKB-569 induced G0-
G1 arrest in SK-Hep1.Kim H, et al.  •  EKB-569 Inhibits SK-Hep1 Cell Proliferation 
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and EGFR following treatment with 1, 2.5, or 5 μM EKB-569 (data 
not shown). 
Effect of combined sorafenib and EKB-569 treatment on 
EGFR-targeted resistant cell line 
We determined whether sorafenib plus EKB-569 could have an 
effect on drug-resistant cell lines. SNU-475 cell line was the most 
resistant to several drugs in our experiments. Therefore, SNU-
475 cells were treated with sorafenib alone, EKB-569 alone, or 
sorafenib plus EKB-569 combination at 0, 0.0033. 0.01, 0.033, 
0.1, 0.33, 1, 3.3, and 10 μM concentrations, respectively, for 72 hr 
(Fig. 3). Cellular viability was measured using the CCK-8 kit. The 
combination of these two agents had a synergistic effect on SNU-
475 cells and the IC50 was 5.1 μM. These results suggest that com-
bined treatment with sorafenib and EKB-569 may have a thera-
peutic effect on hepatoma cells, which were resistant to many 
other molecular-targeted agents.
DISCUSSION
HCC is one of the most resistant tumors for which conventional 
chemotherapy has shown only a minor effect, with response 
rates below 10% (18, 19). Sorafenib has been shown to inhibit 
tumor cell proliferation by blocking the Ras/Raf/MAPK path-
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Fig. 2. EKB-569 decreased the phosphorylation of AKT and ERK at the protein level. 
SK-Hep1 cells were treated with the indicated concentrations of EKB-569 for 24 hr, 
and Western blotting of total-, pERK, total-, pAKT, CDK4, p21, and β-actin (loading 
control) was performed. Immunoblotting for each protein was done at least twice, us-
ing independently prepared lysates.
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Fig. 3. Effect of sorafenib/EKB-569 co-treatment on the EGFR-targeted resistant 
SNU-475 cell line. SNU-475 cells were treated with sorafenib alone, EKB-569 alone, 
or sorafenib plus EKB-569 at the indicated concentrations, for 72 hr. Cellular viability 
was measured using the CCK-8 assay.
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way and to inhibit angiogenesis by blocking both VEGFR and 
PDGFR signaling (6). Therefore, sorafenib was known to be the 
most effective agent in HCC. To identify the new potential anti-
tumor agents on HCC, we screened several drugs, including tar-
geted agents under current ongoing investigation, such as pa-
zopanib, brivanib, EKB-569, elrotinib, gefitinib, and sorafenib 
(9-11). In our results from 13 HCC cell lines, the novel irrevers-
ible EGFR inhibitor EKB-569 showed higher efficacy than first 
generation, reversible EGFR inhibitors (Table 1). To the best of 
our knowledge, this is the first report highlighting the effects of 
EKB-569 on HCC.
  Drugs that alter the cell cycle are of particular interest, since 
cell cycle regulation is the basic mechanism underlying prolifer-
ation, differentiation, and death of cancer cells. Progression of 
cells through the normal cell cycle requires coordinated actions 
of positive and negative factors. Mitogenic signals stimulate se-
quential assembly and activation of cyclin D/CDK4/6 and cy-
clinE/CDK2 in early and late G1, resulting in the phosphoryla-
tion of Rb protein, release of E2F transcription factors, and in-
duction of late-G1-specific genes (20, 21). Because we observed 
inhibition of cell proliferation using a microscope, we examined 
cell cycle arrest by flow cytometry and Western blot analysis in 
SK-Hep1 and SNU475 cells treated with EKB-569 for 24 hr. In 
cells sensitive to novel EGFR-TKI, such as SK-Hep1, only 1 μM 
EKB-569 inhibited proliferation by increasing G0-G1 arrest (Fig. 
1) and caused a dose-dependent decrease in the expression of 
pAKT and pERK and a dose-dependent increase in the expres-
sion of p21 (Fig. 2), but did not change CDK4, cyclin D1, and p27 
(data not shown). Because AKT seemed to play an important 
role in the survival of tumor cells in the present study, AKT may 
be one of the targets in HCC therapy. 
  There are some reports showing that tumorigenesis may be 
related to EGFR mutations, MET amplifications (22), the IGF-1R Kim H, et al.  •  EKB-569 Inhibits SK-Hep1 Cell Proliferation 
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pathway (23), PTEN (24, 25), PIK3CA (26), and KRAS (27) muta-
tions in various cancer cells, but no EGFR mutations in HCC (28, 
29). We also analyzed the PIK3CA exon 20 and KRAS exon 1 in 
13 HCC cell lines. Our results were similar to the effects on wild-
type cells in all 13 HCC cell lines. We did not find any association 
with certain mutations of genes or pathways in both EKB-569 
sensitive and resistant cell lines. Of all 13 HCC cell lines, SNU-475 
was the most resistant to several molecular-targeted agents, in-
cluding EKB-569. We have shown for the first time that sorafenib 
plus EKB-569 has an effect on drug-resistant cell lines. Sorafenib 
(10 μM) or EKB-569 (10 μM) alone could not inhibit cell prolif-
eration, but combination treatment of these agents had a syn-
ergistic effect on SNU-475 cells. This result suggests that com-
bined treatment with sorafenib and EKB-569 represents a prom-
ising strategy to overcome resistance against various EGFR-TKIs 
and sorafenib. EKB-569 alone and in combination with sorafenib 
requires further study to identify the exact signaling pathway. 
Nevertheless, these approaches might have important implica-
tions for the development of a tailored treatment strategy in pa-
tients with highly resistant hepatocellular carcinoma. 
  In this study, we found that EKB-569 had higher efficacy in 
HCC, compared to first generation, reversible EGFR inhibitors. 
Furthermore, the combination of sorafenib and EKB-569 might 
be able to overcome HCC resistance to EGFR inhibitors.
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Novel EGFR-TK Inhibitor EKB-569 Inhibits Hepatocellular Carcinoma Cell 
Proliferation by AKT and MAPK Pathways
Heesue Kim and Ho Yeong Lim
We investigated drugs that can potentially overcome multi-drug resistance in hepatocellular carcinoma (HCC) cells. SK-Hep1 cells 
treated with EKB-569 showed the highest G0-G1 arrest and decreased the phosphorylation of AKT and ERK. The combination of 
sorafenib and EKB-569 showed a synergistic effect to inhibit proliferation of SNU-475, previously the most resistant HCC cell to 
EGFR-Tyrosin kinase inhibitors. These approaches might have important implications for the development of a tailored treatment 
strategy in patients.